Sergiy Fedorov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sergiy Fedorov has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Mykyta Bielinskyi
Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
8 shared publications - Serhii Herashchenko
Івано-Франківський національний медичний університет
8 shared publications - Nestor Seredyuk
Ivano-Frankivsk national medical University, Department of internal medicine №2 and nursing, Ivano-Frankivsk, Ukraine
4 shared publications - I. I. Kozan
Івано-Франківський національний медичний університет, кафедра терапії, сімейної та екстреної медицини післядипломної освіти, м. Івано-Франківськ, Ураїна; Клінічна лікарня «Феофанія», м. Київ, Україна
3 shared publications - Ihor Tomyn
Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
3 shared publications - N. B. Nyshchuk-Oliinyk
Івано-Франківський національний медичний університет
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 33 (Додаток 2 )
Серцево-судинні захворювання та хронічна хвороба нирок. Клінічний експертний консенсус Всеукраїнської асоціації кардіологів України та Української асоціації нефрологів і фахівців з трансплантації нирки
Мета створення клінічного експертного консенсусу – підвищити інформованість кардіологів щодо сповільнення темпів прогресування cерцево-судинних захворювань та хронічної хвороби нирок шляхом впровадження алгоритмів менеджменту таких хворих відповідно до міжнародних і національних настанов, клінічних протоколів та власного досвіду експертів.
- 23 October 2026
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 33 (Додаток 2 )
Open AccessСерцево-судинні захворювання та хронічна хвороба нирок. Клінічний експертний консенсус Всеукраїнської асоціації кардіологів України та Української асоціації нефрологів і фахівців з трансплантації нирки
Мета створення клінічного експертного консенсусу – підвищити інформованість кардіологів щодо сповільнення темпів прогресування cерцево-судинних захворювань та хронічної хвороби нирок шляхом впровадження алгоритмів менеджменту таких хворих відповідно до міжнародних і національних настанов, клінічних протоколів та власного досвіду експертів.
- Open Access
- 31 August 2026
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 33 (4) , 71-80
Консенсус експертів Всеукраїнської асоціації кардіологів України щодо зниження ризику серцево-судинних подій та госпіталізацій у пацієнтів із хронічною серцевою недостатністю із фракцією викиду лівого шлуночка понад 40 % на фоні застосування першого нестероїдного антагоніста мінералокортикоїдних рецепторів
Хронічна серцева недостатність із помірно зниженою або збереженою фракцією викиду лівого шлуночка залишається актуальною медико-соціальною проблемою через високу поширеність, складність діагностики, значний тягар коморбідності та несприятливий прогноз. У цьому консенсусі експертів узагальнено сучасні підходи до діагностики серцевої недостатності зі збереженою фракцією викиду лівого шлуночка, зокрема поетапний діагностичний пошук із використанням клінічної оцінки, ехокардіографічних показників і натрійуретичних пептидів. Окрему увагу приділено обмеженості доказової бази для більшості традиційних медикаментозних стратегій у пацієнтів із фракцією викиду лівого шлуночка ≥ 40 % та потребі в додаткових патогенетично обґрунтованих підходах. Розглянуто роль патологічної гіперактивації мінералокортикоїдних рецепторів у розвитку запалення, фіброзу та ремоделювання міокарда. Представлено клінічні дані щодо фінеренону — інноваційного нестероїдного антагоніста мінералокортикоїдних рецепторів, який у дослідженні FINEARTS-HF продемонстрував зниження на 16 % ризику серцево-судинної смерті та подій, пов’язаних із погіршенням серцевої недостатності, в пацієнтів із фракцією викиду лівого шлуночка ≥ 40 % при сприятливому профілі безпечності. Обґрунтовано доцільність включення фінеренону в майбутній стандарт сучасного лікування серцевої недостатності з помірно зниженою або збереженою фракцією викиду лівого шлуночка в Україні.
- 31 August 2026
- Published by Chetverta Khvylia in Ukrainian Journal of Cardiology
- Vol. 33 (4) , 71-80
Open AccessКонсенсус експертів Всеукраїнської асоціації кардіологів України щодо зниження ризику серцево-судинних подій та госпіталізацій у пацієнтів із хронічною серцевою недостатністю із фракцією викиду лівого шлуночка понад 40 % на фоні застосування першого нестероїдного антагоніста мінералокортикоїдних рецепторів
Хронічна серцева недостатність із помірно зниженою або збереженою фракцією викиду лівого шлуночка залишається актуальною медико-соціальною проблемою через високу поширеність, складність діагностики, значний тягар коморбідності та несприятливий прогноз. У цьому консенсусі експертів узагальнено сучасні підходи до діагностики серцевої недостатності зі збереженою фракцією викиду лівого шлуночка, зокрема поетапний діагностичний пошук із використанням клінічної оцінки, ехокардіографічних показників і натрійуретичних пептидів. Окрему увагу приділено обмеженості доказової бази для більшості традиційних медикаментозних стратегій у пацієнтів із фракцією викиду лівого шлуночка ≥ 40 % та потребі в додаткових патогенетично обґрунтованих підходах. Розглянуто роль патологічної гіперактивації мінералокортикоїдних рецепторів у розвитку запалення, фіброзу та ремоделювання міокарда. Представлено клінічні дані щодо фінеренону — інноваційного нестероїдного антагоніста мінералокортикоїдних рецепторів, який у дослідженні FINEARTS-HF продемонстрував зниження на 16 % ризику серцево-судинної смерті та подій, пов’язаних із погіршенням серцевої недостатності, в пацієнтів із фракцією викиду лівого шлуночка ≥ 40 % при сприятливому профілі безпечності. Обґрунтовано доцільність включення фінеренону в майбутній стандарт сучасного лікування серцевої недостатності з помірно зниженою або збереженою фракцією викиду лівого шлуночка в Україні.
- Open Access
- 28 June 2026
- Published by Ivano-Frankivsk National Medical University in Art of Medicine
- p. 34-40
ВПЛИВ ДОДАВАННЯ ЕМПАГЛІФЛОЗИНУ ДО СТАНДАРТНОЇ ТЕРАПІЇ НА ЕХОКАРДІОГРАФІЧНІ ПОКАЗНИКИ ТА БІОМАРКЕРИ У ПАЦІЄНТІВ З ІНФАРКТОМ МІОКАРДА ТА ЗНИЖЕНОЮ ФРАКЦІЄЮ ВИКИДУ ЛІВОГО ШЛУНОЧКА
The aim of the study was to assess changes in echocardiographic parameters together with biomarkers of myocardial injury, hemodynamic stress, systemic inflammation and fibrosis in patients with reduced left ventricular ejection fraction after myocardial infarction. The investigation was performed at the Feofaniya Clinical Hospital and included patients with left ventricular ejection fraction below 40 % who were assigned either to guideline-based standard therapy or to standard treatment supplemented with empagliflozin. Before and after treatment, left ventricular ejection fraction, global longitudinal strain, indices of diastolic function, left atrial volume index, relative wall thickness and left ventricular myocardial mass index were evaluated, along with serum levels of hsCRP, NT-proBNP, hsTroponin I, GDF-15 and galectin-3, as well as integrated inflammatory indices NLR, PLR, SII, SIRI and AISI. Baseline clinical and anamnestic characteristics were generally comparable between groups, with the exception of a higher rate of uncontrolled hypertension in the empagliflozin group. After treatment, patients who received empagliflozin demonstrated a more pronounced improvement in left ventricular systolic performance and myocardial deformation, with significantly better post-treatment values and greater relative changes in ejection fraction and global longitudinal strain. A more favorable tendency was also observed for diastolic function and structural remodeling parameters. In addition, the empagliflozin group showed a larger reduction in NT-proBNP, hsTroponin I, hsCRP and GDF-15, as well as a more substantial decline in integrated inflammatory indices, particularly NLR, SII, SIRI and AISI. These findings suggest that the addition of empagliflozin to standard therapy in patients with myocardial infarction and left ventricular ejection fraction below 41 % may positively influence early post-infarction myocardial remodeling, attenuate inflammatory activation and reduce hemodynamic stress. The results support the view that empagliflozin may be considered a promising component of early cardiometabolic management in this high-risk category of patients, although larger prospective studies with longer follow-up are required to confirm its influence on hard clinical outcomes. In patients hospitalized with myocardial infarction and LVEF ≤40 %, the addition of empagliflozin to standard therapy was associated with a more pronounced improvement in left ventricular systolic function, manifested by significantly better changes in LVEF and GLS. Against the background of empagliflozin therapy, a more favorable dynamic of hemodynamic load and myocardial injury markers was observed, particularly NT-proBNP and hsTroponin I, as well as a more substantial reduction in hsCRP. The inclusion of empagliflozin in the treatment regimen was accompanied by a more pronounced decrease in the integrated inflammatory indices NLR, SII, SIRI, and AISI, indicating a potential beneficial effect of the drug on the systemic immune-inflammatory response in the early post-infarction period. The greater reduction in GDF-15 and the trend toward a more marked decrease in galectin-3 in the combination therapy group suggest a possible favorable effect of empagliflozin on post-infarction remodeling and myocardial fibrosis.
- 28 June 2026
- Published by Ivano-Frankivsk National Medical University in Art of Medicine
- p. 34-40
Open AccessВПЛИВ ДОДАВАННЯ ЕМПАГЛІФЛОЗИНУ ДО СТАНДАРТНОЇ ТЕРАПІЇ НА ЕХОКАРДІОГРАФІЧНІ ПОКАЗНИКИ ТА БІОМАРКЕРИ У ПАЦІЄНТІВ З ІНФАРКТОМ МІОКАРДА ТА ЗНИЖЕНОЮ ФРАКЦІЄЮ ВИКИДУ ЛІВОГО ШЛУНОЧКА
The aim of the study was to assess changes in echocardiographic parameters together with biomarkers of myocardial injury, hemodynamic stress, systemic inflammation and fibrosis in patients with reduced left ventricular ejection fraction after myocardial infarction. The investigation was performed at the Feofaniya Clinical Hospital and included patients with left ventricular ejection fraction below 40 % who were assigned either to guideline-based standard therapy or to standard treatment supplemented with empagliflozin. Before and after treatment, left ventricular ejection fraction, global longitudinal strain, indices of diastolic function, left atrial volume index, relative wall thickness and left ventricular myocardial mass index were evaluated, along with serum levels of hsCRP, NT-proBNP, hsTroponin I, GDF-15 and galectin-3, as well as integrated inflammatory indices NLR, PLR, SII, SIRI and AISI. Baseline clinical and anamnestic characteristics were generally comparable between groups, with the exception of a higher rate of uncontrolled hypertension in the empagliflozin group. After treatment, patients who received empagliflozin demonstrated a more pronounced improvement in left ventricular systolic performance and myocardial deformation, with significantly better post-treatment values and greater relative changes in ejection fraction and global longitudinal strain. A more favorable tendency was also observed for diastolic function and structural remodeling parameters. In addition, the empagliflozin group showed a larger reduction in NT-proBNP, hsTroponin I, hsCRP and GDF-15, as well as a more substantial decline in integrated inflammatory indices, particularly NLR, SII, SIRI and AISI. These findings suggest that the addition of empagliflozin to standard therapy in patients with myocardial infarction and left ventricular ejection fraction below 41 % may positively influence early post-infarction myocardial remodeling, attenuate inflammatory activation and reduce hemodynamic stress. The results support the view that empagliflozin may be considered a promising component of early cardiometabolic management in this high-risk category of patients, although larger prospective studies with longer follow-up are required to confirm its influence on hard clinical outcomes. In patients hospitalized with myocardial infarction and LVEF ≤40 %, the addition of empagliflozin to standard therapy was associated with a more pronounced improvement in left ventricular systolic function, manifested by significantly better changes in LVEF and GLS. Against the background of empagliflozin therapy, a more favorable dynamic of hemodynamic load and myocardial injury markers was observed, particularly NT-proBNP and hsTroponin I, as well as a more substantial reduction in hsCRP. The inclusion of empagliflozin in the treatment regimen was accompanied by a more pronounced decrease in the integrated inflammatory indices NLR, SII, SIRI, and AISI, indicating a potential beneficial effect of the drug on the systemic immune-inflammatory response in the early post-infarction period. The greater reduction in GDF-15 and the trend toward a more marked decrease in galectin-3 in the combination therapy group suggest a possible favorable effect of empagliflozin on post-infarction remodeling and myocardial fibrosis.
- Open Access
- 11 June 2026
- Published by Zaporizhzhia State Medical and Pharmaceutical University
- Vol. 28 (3) , 194-199
Concept of venous thromboembolism prophylaxis following endovenous thermal procedures for chronic venous disease of the lower limbs
Aim. To enhance the safety and efficacy of thermal ablation procedures in patients with chronic venous disease (CVD) of the lower limbs by developing a strategy for venous thromboembolism (VTE) prevention. Materials and methods. This single-center, prospective, open-label study included 420 consecutive patients with CVD (C2–C6). Participants underwent radiofrequency ablation (RFA, n = 206) or endovenous laser ablation (EVLA, n = 214). At the first stage, VTE risk stratification was conducted using the Caprini scale; at the second stage, the optimal thromboprophylaxis algorithm was selected. Patients were divided into two homogeneous groups. Group 1 (208 patients) received VTE prevention with standard elastic compression only, while Group 2 (212 patients) received prophylaxis based on the proposed algorithm. The incidence of postoperative VTE and bleeding complications was assessed. Results. According to VTE risk stratification, 23.6 % of patients were classified as low risk, 63.1 % as moderate risk, 9.0 % as high risk, 3.1 % as very high risk, and 1.2 % as the highest risk. Based on the second phase analysis, 12 patients (2.9 %) of Group 1 developed thrombotic complications during the early postoperative period: EHIT class II was diagnosed in 3 cases (0.7 %) after EVLA and in 2 cases (0.5 %) after RFA. Additionally, distal deep vein thrombosis (DVT) was detected in 7 patients (1.7 %) with high VTE risk on postoperative day 7: 3 after EVLA and 4 after RFA. Implementation of the proposed thromboprophylaxis strategy significantly reduced the total incidence of thrombotic complications compared to Group 1 (0.4 % vs. 2.9 %; p = 0.031). In Group 2, only one patient (0.4 %) with moderate VTE risk was diagnosed with distal DVT. Among 39 patients (18.3 %) who received prophylactic acetylsalicylic acid or rivaroxaban, a statistically significant increase in ecchymosis occurrence was observed (p = 0.018). Conclusions. Implementing a differentiated, risk-oriented thromboprophylaxis strategy significantly (p = 0.031) reduced the incidence of VTE from 2.9 % to 0.4 %, p = 0.031, without increasing the risk of clinically significant bleeding.
- 11 June 2026
- Published by Zaporizhzhia State Medical and Pharmaceutical University
- Vol. 28 (3) , 194-199
Open AccessConcept of venous thromboembolism prophylaxis following endovenous thermal procedures for chronic venous disease of the lower limbs
Aim. To enhance the safety and efficacy of thermal ablation procedures in patients with chronic venous disease (CVD) of the lower limbs by developing a strategy for venous thromboembolism (VTE) prevention. Materials and methods. This single-center, prospective, open-label study included 420 consecutive patients with CVD (C2–C6). Participants underwent radiofrequency ablation (RFA, n = 206) or endovenous laser ablation (EVLA, n = 214). At the first stage, VTE risk stratification was conducted using the Caprini scale; at the second stage, the optimal thromboprophylaxis algorithm was selected. Patients were divided into two homogeneous groups. Group 1 (208 patients) received VTE prevention with standard elastic compression only, while Group 2 (212 patients) received prophylaxis based on the proposed algorithm. The incidence of postoperative VTE and bleeding complications was assessed. Results. According to VTE risk stratification, 23.6 % of patients were classified as low risk, 63.1 % as moderate risk, 9.0 % as high risk, 3.1 % as very high risk, and 1.2 % as the highest risk. Based on the second phase analysis, 12 patients (2.9 %) of Group 1 developed thrombotic complications during the early postoperative period: EHIT class II was diagnosed in 3 cases (0.7 %) after EVLA and in 2 cases (0.5 %) after RFA. Additionally, distal deep vein thrombosis (DVT) was detected in 7 patients (1.7 %) with high VTE risk on postoperative day 7: 3 after EVLA and 4 after RFA. Implementation of the proposed thromboprophylaxis strategy significantly reduced the total incidence of thrombotic complications compared to Group 1 (0.4 % vs. 2.9 %; p = 0.031). In Group 2, only one patient (0.4 %) with moderate VTE risk was diagnosed with distal DVT. Among 39 patients (18.3 %) who received prophylactic acetylsalicylic acid or rivaroxaban, a statistically significant increase in ecchymosis occurrence was observed (p = 0.018). Conclusions. Implementing a differentiated, risk-oriented thromboprophylaxis strategy significantly (p = 0.031) reduced the incidence of VTE from 2.9 % to 0.4 %, p = 0.031, without increasing the risk of clinically significant bleeding.
- Open Access
- 28 May 2026
- Published by NGO Allukrainian Association of Endovascular Neuroradiology in Ukrainian Interventional Neuroradiology and Surgery
- Vol. 56 (2)
Effect of adding empagliflozin to standard therapy in patients with myocardial infarction and left ventricular ejection fraction >40 %: echocardiographic and biomarker changes
Objective. To evaluate the effect of adding empagliflozin to standard therapy in patients admitted with myocardial infarction with concomitant heart failure with left ventricular ejection fraction >40 % (mid-range and preserved) on echocardiographic parameters and biomarkers reflecting myocardial injury, hemodynamic stress, systemic inflammation, and fibrosis.Materials and methods. The study included patients hospitalized for myocardial infarction at Feofaniya Clinical Hospital. Guideline-directed medical therapy (GDMT) group consisted of patients with myocardial infarction and heart failure with mid-range ejection fraction (HFmrEF)/ heart failure with preserved ejection fraction (HFpEF) who received standard treatment. GDMT + E (GDMT + empagliflozin) group included patients with myocardial infarction and HFmrEF/HFpEF who received standard treatment plus empagliflozin. Baseline clinical and anamnestic characteristics were assessed before treatment. Echocardiography included left ventricular ejection fraction, global longitudinal strain, E/e′, deceleration time, left atrial volume index, relative wall thickness, and left ventricular mass index. Laboratory assessment included high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, high-sensitivity troponin I, growth differentiation factor 15, galectin-3, and inflammatory indices (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and aggregate index of systemic inflammation). Quantitative data are presented as mean ± standard deviation. Student’s t-test was used for independent-group comparisons, paired t-test for within-group comparisons, and χ² test for qualitative variables. Differences were considered significant at p<0.05.Results. At baseline, GDMT and GDMT + E groups were comparable in age, sex, infarction presentation, Killip class, extent of coronary involvement, major complaints, and comorbidities. After treatment, patients receiving empagliflozin demonstrated more pronounced improvement in systolic function and myocardial deformation. Left ventricular ejection fraction increased from 48.0 ± 4.1 % to 51.8 ± 4.0 % in GDMT + E group versus from 47.8 ± 4.2 % to 49.9 ± 4.2 % in GDMT group, with a significant between-group difference after treatment (p=0.049). Global longitudinal strain also improved more markedly in GDMT + E group (from 14.2 ± 1.9 % to 16.0 ± 1.9 %) than in GDMT group (from 14.0 ± 2.0 % to 15.1 ± 1.9 %; p=0.045). More favorable changes were also observed for high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, high-sensitivity troponin I, growth differentiation factor 15, galectin-3, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and aggregate index of systemic inflammation, with significantly lower post-treatment values in the empagliflozin group for most of these markers. Conclusions. In patients admitted with myocardial infarction and HFmrEF/HFpEF, the addition of empagliflozin to standard therapy was associated with a more favorable recovery of left ventricular systolic function, better myocardial deformation indices, and a more pronounced reduction in biomarkers of inflammation, myocardial stress, injury, and fibrosis. These findings support the potential role of empagliflozin as an adjunctive cardiometabolic strategy in post-infarction patients and warrants follow-up studies of potential class-effect of sodium-glucose cotransporter 2inhibitors.
- 28 May 2026
- Published by NGO Allukrainian Association of Endovascular Neuroradiology in Ukrainian Interventional Neuroradiology and Surgery
- Vol. 56 (2)
Open AccessEffect of adding empagliflozin to standard therapy in patients with myocardial infarction and left ventricular ejection fraction >40 %: echocardiographic and biomarker changes
Objective. To evaluate the effect of adding empagliflozin to standard therapy in patients admitted with myocardial infarction with concomitant heart failure with left ventricular ejection fraction >40 % (mid-range and preserved) on echocardiographic parameters and biomarkers reflecting myocardial injury, hemodynamic stress, systemic inflammation, and fibrosis.Materials and methods. The study included patients hospitalized for myocardial infarction at Feofaniya Clinical Hospital. Guideline-directed medical therapy (GDMT) group consisted of patients with myocardial infarction and heart failure with mid-range ejection fraction (HFmrEF)/ heart failure with preserved ejection fraction (HFpEF) who received standard treatment. GDMT + E (GDMT + empagliflozin) group included patients with myocardial infarction and HFmrEF/HFpEF who received standard treatment plus empagliflozin. Baseline clinical and anamnestic characteristics were assessed before treatment. Echocardiography included left ventricular ejection fraction, global longitudinal strain, E/e′, deceleration time, left atrial volume index, relative wall thickness, and left ventricular mass index. Laboratory assessment included high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, high-sensitivity troponin I, growth differentiation factor 15, galectin-3, and inflammatory indices (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and aggregate index of systemic inflammation). Quantitative data are presented as mean ± standard deviation. Student’s t-test was used for independent-group comparisons, paired t-test for within-group comparisons, and χ² test for qualitative variables. Differences were considered significant at p<0.05.Results. At baseline, GDMT and GDMT + E groups were comparable in age, sex, infarction presentation, Killip class, extent of coronary involvement, major complaints, and comorbidities. After treatment, patients receiving empagliflozin demonstrated more pronounced improvement in systolic function and myocardial deformation. Left ventricular ejection fraction increased from 48.0 ± 4.1 % to 51.8 ± 4.0 % in GDMT + E group versus from 47.8 ± 4.2 % to 49.9 ± 4.2 % in GDMT group, with a significant between-group difference after treatment (p=0.049). Global longitudinal strain also improved more markedly in GDMT + E group (from 14.2 ± 1.9 % to 16.0 ± 1.9 %) than in GDMT group (from 14.0 ± 2.0 % to 15.1 ± 1.9 %; p=0.045). More favorable changes were also observed for high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, high-sensitivity troponin I, growth differentiation factor 15, galectin-3, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and aggregate index of systemic inflammation, with significantly lower post-treatment values in the empagliflozin group for most of these markers. Conclusions. In patients admitted with myocardial infarction and HFmrEF/HFpEF, the addition of empagliflozin to standard therapy was associated with a more favorable recovery of left ventricular systolic function, better myocardial deformation indices, and a more pronounced reduction in biomarkers of inflammation, myocardial stress, injury, and fibrosis. These findings support the potential role of empagliflozin as an adjunctive cardiometabolic strategy in post-infarction patients and warrants follow-up studies of potential class-effect of sodium-glucose cotransporter 2inhibitors.
- Open Access
- 14 March 2026
- Published by Vinnytsia National Pyrogov Memorial Medical University in Reports of Morphology
- Vol. 32 (1) , 26-31
Empagliflozin attenuates post-injury myocardial remodeling in a rat isoproterenol model: a morphological and morphometric study
Adverse post-myocardial infarction remodeling is a key pathway toward chronic heart failure. While sodium-glucose cotransporter-2 (SGLT2) inhibitors improve outcomes in heart failure, evidence on their structural effects when therapy is initiated after the acute injury phase remains limited. Study aim – to evaluate whether delayed initiation of empagliflozin attenuates histological remodeling features and reduces morphometric indices of cardiomyocyte hypertrophy in rats with isoproterenol-induced myocardial injury. Sixty male outbred white rats (200-250 g) were allocated to three groups (n=20 each): intact control, isoproterenol (ISO) + placebo, and ISO + empagliflozin. Myocardial injury was induced by ISO (85 mg/kg/day, subcutaneously, on days 0 and 1). From day 14, animals received empagliflozin (10 mg/kg/day by oral gavage) or vehicle for 30 days. Hearts were harvested on day 44. Left-ventricular sections were obtained from subendocardial, intramural, and subepicardial layers and stained with hematoxylin-eosin and Masson’s trichrome. Digital morphometry quantified cardiomyocyte and nuclear area. Statistical analysis was conducted using the IBM SPSS 26.0 software (IBM, USA). It was established that ISO caused microvascular congestion, interstitial edema, cardiomyocyte disarray, and increased collagen deposition on Masson’s staining. Delayed empagliflozin reduced the qualitative severity of injury and attenuated hypertrophic morphometry. Cardiomyocyte area was higher in ISO + placebo than in control (342.8±12.5 μm² vs 223.2±8.4 μm²; p<0.01) and decreased in ISO + empagliflozin (287.4±8.3 μm²; p<0.05 vs ISO + placebo), while remaining above control. Nuclear area followed a similar pattern (36.95±1.07 μm² vs 20.73±0.54 μm² in ISO + placebo and 26.81±0.65 μm² with empagliflozin). Acquired data suggests that delayed empagliflozin use after the experimental myocardial damage partially alleviates structural remodelling and morphometric signs of cardiomyocyte hypertrophy.
- 14 March 2026
- Published by Vinnytsia National Pyrogov Memorial Medical University in Reports of Morphology
- Vol. 32 (1) , 26-31
Open AccessEmpagliflozin attenuates post-injury myocardial remodeling in a rat isoproterenol model: a morphological and morphometric study
Adverse post-myocardial infarction remodeling is a key pathway toward chronic heart failure. While sodium-glucose cotransporter-2 (SGLT2) inhibitors improve outcomes in heart failure, evidence on their structural effects when therapy is initiated after the acute injury phase remains limited. Study aim – to evaluate whether delayed initiation of empagliflozin attenuates histological remodeling features and reduces morphometric indices of cardiomyocyte hypertrophy in rats with isoproterenol-induced myocardial injury. Sixty male outbred white rats (200-250 g) were allocated to three groups (n=20 each): intact control, isoproterenol (ISO) + placebo, and ISO + empagliflozin. Myocardial injury was induced by ISO (85 mg/kg/day, subcutaneously, on days 0 and 1). From day 14, animals received empagliflozin (10 mg/kg/day by oral gavage) or vehicle for 30 days. Hearts were harvested on day 44. Left-ventricular sections were obtained from subendocardial, intramural, and subepicardial layers and stained with hematoxylin-eosin and Masson’s trichrome. Digital morphometry quantified cardiomyocyte and nuclear area. Statistical analysis was conducted using the IBM SPSS 26.0 software (IBM, USA). It was established that ISO caused microvascular congestion, interstitial edema, cardiomyocyte disarray, and increased collagen deposition on Masson’s staining. Delayed empagliflozin reduced the qualitative severity of injury and attenuated hypertrophic morphometry. Cardiomyocyte area was higher in ISO + placebo than in control (342.8±12.5 μm² vs 223.2±8.4 μm²; p<0.01) and decreased in ISO + empagliflozin (287.4±8.3 μm²; p<0.05 vs ISO + placebo), while remaining above control. Nuclear area followed a similar pattern (36.95±1.07 μm² vs 20.73±0.54 μm² in ISO + placebo and 26.81±0.65 μm² with empagliflozin). Acquired data suggests that delayed empagliflozin use after the experimental myocardial damage partially alleviates structural remodelling and morphometric signs of cardiomyocyte hypertrophy.
- Open Access
- 4 November 2025
- Published by Poltava State Medical University (PSMU) in Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії
- Vol. 25 (3) , 60-64
THE ROLE OF THE GUT MICROBIOME IN THE COURSE OF STABLE CORONARY HEART DISEASE
The aim of this study was to investigate the relationship between the clinical features of stable ischemic heart disease and quantitative as well as qualitative changes in the intestinal microbiome. Participants and Methods. The study included 39 patients with stable ischemic heart disease (mean age 67.84 ± 14.26 years; 20 women and 19 men). Participants were divided into two groups: patients with intestinal microbiocenosis abnormalities (n = 23) and a control group with normal intestinal microflora (n = 16). Results. The main cause of dysbiosis was found to be an increased total number of Escherichia coli, observed in 86.95% of patients with intestinal dysbiosis. The mean total E. coli count in this group was 7.165 × 10¹⁰. A decrease in bifidobacteria was detected in 43.47% of patients, while reduced lactobacteria were noted in 39.13%. Among the opportunistic flora contributing to dysbiosis, the most common isolates were Klebsiella oxytoca (35.71%), Citrobacter amalonaticus (21.4%), Citrobacter freundii (7.14%), and Geotrichum candidum (21.42%). The mean ejection fraction, measured by Simpson’s biplane disk summation, was significantly lower in patients with dysbiosis compared with those without (47.13 ± 8.38% vs. 52.06 ± 6.07%; p = 0.0388). Multivessel lesions were present in 43.47% of patients with dysbiosis compared with 6.25% of patients with normal intestinal microflora (χ² = 4.75; p = 0.029). Severe dyspnea was reported by 78.26% of patients in the dysbiosis group versus 37.5% in the control group (χ² = 8.57; p = 0.0034). Retrosternal pain was also significantly more common in the dysbiosis group (73.91%) compared with the control group (31.25%; χ² = 6.99; p = 0.0082). Conclusion. In patients with stable coronary artery disease (angina pectoris, FC II–III) and intestinal dysbiosis, the most significant indicator of microbiota disturbance was Escherichia coli. Dysbiosis was associated with more pronounced angina symptoms, reduced left ventricular ejection fraction, increased left ventricular size, and served as an independent risk factor for multivessel coronary artery disease.
- 4 November 2025
- Published by Poltava State Medical University (PSMU) in Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії
- Vol. 25 (3) , 60-64
Open AccessTHE ROLE OF THE GUT MICROBIOME IN THE COURSE OF STABLE CORONARY HEART DISEASE
The aim of this study was to investigate the relationship between the clinical features of stable ischemic heart disease and quantitative as well as qualitative changes in the intestinal microbiome. Participants and Methods. The study included 39 patients with stable ischemic heart disease (mean age 67.84 ± 14.26 years; 20 women and 19 men). Participants were divided into two groups: patients with intestinal microbiocenosis abnormalities (n = 23) and a control group with normal intestinal microflora (n = 16). Results. The main cause of dysbiosis was found to be an increased total number of Escherichia coli, observed in 86.95% of patients with intestinal dysbiosis. The mean total E. coli count in this group was 7.165 × 10¹⁰. A decrease in bifidobacteria was detected in 43.47% of patients, while reduced lactobacteria were noted in 39.13%. Among the opportunistic flora contributing to dysbiosis, the most common isolates were Klebsiella oxytoca (35.71%), Citrobacter amalonaticus (21.4%), Citrobacter freundii (7.14%), and Geotrichum candidum (21.42%). The mean ejection fraction, measured by Simpson’s biplane disk summation, was significantly lower in patients with dysbiosis compared with those without (47.13 ± 8.38% vs. 52.06 ± 6.07%; p = 0.0388). Multivessel lesions were present in 43.47% of patients with dysbiosis compared with 6.25% of patients with normal intestinal microflora (χ² = 4.75; p = 0.029). Severe dyspnea was reported by 78.26% of patients in the dysbiosis group versus 37.5% in the control group (χ² = 8.57; p = 0.0034). Retrosternal pain was also significantly more common in the dysbiosis group (73.91%) compared with the control group (31.25%; χ² = 6.99; p = 0.0082). Conclusion. In patients with stable coronary artery disease (angina pectoris, FC II–III) and intestinal dysbiosis, the most significant indicator of microbiota disturbance was Escherichia coli. Dysbiosis was associated with more pronounced angina symptoms, reduced left ventricular ejection fraction, increased left ventricular size, and served as an independent risk factor for multivessel coronary artery disease.
- Open Access
- 1 July 2025
- Published by Ivano-Frankivsk National Medical University in Art of Medicine
- p. 46-52
ВПЛИВ НЕАЛКОГОЛЬНОЇ ЖИРОВОЇ ХВОРОБИ ПЕЧІНКИ НА СТРУКТУРНО-ФУНКЦІОНАЛЬНІ ПАРАМЕТРИ МІОКАРДА НА ТЛІ ХРОНІЧНОГО НИЗЬКОІНТЕНСИВНОГО ЗАПАЛЕННЯ У ПАЦІЄНТІВ ІЗ СТАБІЛЬНОЮ ІШЕМІЧНОЮ ХВОРОБОЮ СЕРЦЯ РІЗНИХ СЦЕНАРІЇВ
Nonalcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disorder, encompassing a continuum of pathologies ranging from simple hepatic steatosis to nonalcoholic steatohepatitis, cirrhosis, and ultimately hepatocellular carcinoma. In parallel, stable coronary artery disease (SCAD) remains one of the leading causes of morbidity and mortality worldwide, in part because of shared cardiometabolic risk factors such as central obesity, insulin resistance, and chronic subclinical inflammation. Previous investigations have demonstrated that NAFLD can act as an independent predictor of coronary artery disease and can accelerate adverse changes in myocardial structure and function. Although NAFLD is primarily associated with hepatic steatosis, its underlying inflammatory and metabolic disturbances extend beyond the liver, promoting systemic low-grade inflammation that may exacerbate left ventricular (LV) remodeling, diastolic dysfunction, and atherogenesis. Aim of the study was the evaluation of the features of LV myocardial remodeling against the background of chronic systemic inflammation in patients with stable coronary heart disease in combination with non-alcoholic fatty liver disease A prospective, controlled study was conducted at the therapeutic department of Ivano-Frankivsk City Clinical Hospital No.1 between January 2022 and December 2024. One hundred twenty-six patients (age ≥18 years) were enrolled and divided into two cohorts: Group I (n = 32): Patients diagnosed with SCAD according to the unified clinical protocol “Stable Ischemic Heart Disease” (Ministry of Health of Ukraine, 2021-2857); Group II (n = 96): Patients with SCAD plus ultrasonographically and biochemically confirmed NAFLD, following the protocol “Nonalcoholic Steatohepatitis” (Ministry of Health of Ukraine, 2014-826). Patients in Group II (SCAD + NAFLD) had a lower mean age (54 vs. 60 years; p = 0.002) yet exhibited higher body weight, body mass index, and waist circumference (p < 0.05). Their functional capacity was significantly reduced: lower mean VO₂ (27.20 vs. 31.30 mL/kg/min; p < 0.001) and METs (7.90 vs. 8.50; p = 0.009), suggesting decreased exercise tolerance. Echocardiography revealed a more pronounced LV remodeling in Group II, with a significantly higher left ventricular mass (189.39 g vs. 172.97 g; p < 0.001) and LVMI (91.42 vs. 87.58 g/m²; p < 0.001). Ejection fraction was mildly but significantly lower (55.02% vs. 58.70%; p < 0.001). Indicators of diastolic dysfunction (lower E/A and higher E/e′) were also worse in Group II, accompanied by a higher LAVI, denoting left atrial enlargement (p = 0.032). In terms of inflammation, SII (644.80 vs. 588.41; p = 0.002) and PLR (198.38 vs. 178.72; p = 0.022) were significantly elevated among patients with combined SCAD and NAFLD, although NLR and LMR did not differ markedly between groups. Lipid profile analysis indicated higher total cholesterol, LDL-cholesterol, VLDL-cholesterol, and triglycerides (all p < 0.01), alongside lower HDL-cholesterol (p < 0.001) in Group II. These changes were reflected in an increased atherogenic coefficient and a higher TyG index (4.00 vs. 3.88; p < 0.001). This study demonstrates that NAFLD amplifies myocardial remodeling and functional impairment in patients with SCAD, coinciding with heightened systemic low-grade inflammation and more severe dyslipidemia.
- 1 July 2025
- Published by Ivano-Frankivsk National Medical University in Art of Medicine
- p. 46-52
Open AccessВПЛИВ НЕАЛКОГОЛЬНОЇ ЖИРОВОЇ ХВОРОБИ ПЕЧІНКИ НА СТРУКТУРНО-ФУНКЦІОНАЛЬНІ ПАРАМЕТРИ МІОКАРДА НА ТЛІ ХРОНІЧНОГО НИЗЬКОІНТЕНСИВНОГО ЗАПАЛЕННЯ У ПАЦІЄНТІВ ІЗ СТАБІЛЬНОЮ ІШЕМІЧНОЮ ХВОРОБОЮ СЕРЦЯ РІЗНИХ СЦЕНАРІЇВ
Nonalcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disorder, encompassing a continuum of pathologies ranging from simple hepatic steatosis to nonalcoholic steatohepatitis, cirrhosis, and ultimately hepatocellular carcinoma. In parallel, stable coronary artery disease (SCAD) remains one of the leading causes of morbidity and mortality worldwide, in part because of shared cardiometabolic risk factors such as central obesity, insulin resistance, and chronic subclinical inflammation. Previous investigations have demonstrated that NAFLD can act as an independent predictor of coronary artery disease and can accelerate adverse changes in myocardial structure and function. Although NAFLD is primarily associated with hepatic steatosis, its underlying inflammatory and metabolic disturbances extend beyond the liver, promoting systemic low-grade inflammation that may exacerbate left ventricular (LV) remodeling, diastolic dysfunction, and atherogenesis. Aim of the study was the evaluation of the features of LV myocardial remodeling against the background of chronic systemic inflammation in patients with stable coronary heart disease in combination with non-alcoholic fatty liver disease A prospective, controlled study was conducted at the therapeutic department of Ivano-Frankivsk City Clinical Hospital No.1 between January 2022 and December 2024. One hundred twenty-six patients (age ≥18 years) were enrolled and divided into two cohorts: Group I (n = 32): Patients diagnosed with SCAD according to the unified clinical protocol “Stable Ischemic Heart Disease” (Ministry of Health of Ukraine, 2021-2857); Group II (n = 96): Patients with SCAD plus ultrasonographically and biochemically confirmed NAFLD, following the protocol “Nonalcoholic Steatohepatitis” (Ministry of Health of Ukraine, 2014-826). Patients in Group II (SCAD + NAFLD) had a lower mean age (54 vs. 60 years; p = 0.002) yet exhibited higher body weight, body mass index, and waist circumference (p < 0.05). Their functional capacity was significantly reduced: lower mean VO₂ (27.20 vs. 31.30 mL/kg/min; p < 0.001) and METs (7.90 vs. 8.50; p = 0.009), suggesting decreased exercise tolerance. Echocardiography revealed a more pronounced LV remodeling in Group II, with a significantly higher left ventricular mass (189.39 g vs. 172.97 g; p < 0.001) and LVMI (91.42 vs. 87.58 g/m²; p < 0.001). Ejection fraction was mildly but significantly lower (55.02% vs. 58.70%; p < 0.001). Indicators of diastolic dysfunction (lower E/A and higher E/e′) were also worse in Group II, accompanied by a higher LAVI, denoting left atrial enlargement (p = 0.032). In terms of inflammation, SII (644.80 vs. 588.41; p = 0.002) and PLR (198.38 vs. 178.72; p = 0.022) were significantly elevated among patients with combined SCAD and NAFLD, although NLR and LMR did not differ markedly between groups. Lipid profile analysis indicated higher total cholesterol, LDL-cholesterol, VLDL-cholesterol, and triglycerides (all p < 0.01), alongside lower HDL-cholesterol (p < 0.001) in Group II. These changes were reflected in an increased atherogenic coefficient and a higher TyG index (4.00 vs. 3.88; p < 0.001). This study demonstrates that NAFLD amplifies myocardial remodeling and functional impairment in patients with SCAD, coinciding with heightened systemic low-grade inflammation and more severe dyslipidemia.
- Open Access
- 22 May 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (3) , 253-258
Cardioprotective effects of sodium-glucose transport protein 2 inhibitors in patients with breast cancer and concomitant type 2 diabetes mellitus undergoing chemotherapy
Background. Breast cancer continues to be the most frequently diagnosed malignancy among women globally, with millions of new cases identified each year. Despite significant advances in chemotherapy that have considerably enhanced survival rates, these improvements are often accompanied by adverse effects that may jeopardize long-term health. One of the most concerning complications is cardiotoxicity, which can range from subtle, asymptomatic alterations in cardiac function to overt, severe heart failure. This study purposed to evaluate the impact of sodium-glucose transport protein 2 inhibitors (SGLT2) inhibitors on diastolic function and endothelial health in breast cancer patients receiving chemotherapy. Materials and methods. A prospective, comparative, study was conducted at Ivano-Frankivsk Central City Clinical Hospital, Private Medical Center “Frankomed” and Lviv Private Medical Center “Rhythm” from January 2023 to May 2024. Fifty-five female patients with confirmed breast cancer and type 2 diabetes mellitus who were referred to cardiologist were enrolled and divided into three groups: group 1 (control, n = 27) received no SGLT2 inhibitors, group 2 (n = 15) received empagliflozin 10 mg daily, and group 3 (n = 13) received dapagliflozin. Echocardiographic assessments and flow-mediated dilation measurements were performed before chemotherapy initiation and after its completion. Results. The control group exhibited a significant deterioration in diastolic function, evidenced by a substantial decrease in the E/A ratio and an increase in the E/e’ ratio and isovolumetric relaxation time. In contrast, both empagliflozin and dapagliflozin groups maintained better diastolic profiles and endothelial function, as shown by less pronounced changes in echocardiographic parameters and flow-mediated dilation. Logistic regression confirmed that patients in the control group had significantly higher odds of developing abnormal follow-up indices compared with those receiving SGLT2 inhibitors. Additionally, a potential class effect was observed, with both agents offering cardioprotective benefits while exhibiting subtle differences in their impact. Conclusions. SGLT2 inhibitors appear to mitigate chemotherapy-induced cardiotoxicity by preserving diastolic function and endothelial health in patients with breast cancer concomitant with type 2 diabetes mellitus.
- 22 May 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (3) , 253-258
Open AccessCardioprotective effects of sodium-glucose transport protein 2 inhibitors in patients with breast cancer and concomitant type 2 diabetes mellitus undergoing chemotherapy
Background. Breast cancer continues to be the most frequently diagnosed malignancy among women globally, with millions of new cases identified each year. Despite significant advances in chemotherapy that have considerably enhanced survival rates, these improvements are often accompanied by adverse effects that may jeopardize long-term health. One of the most concerning complications is cardiotoxicity, which can range from subtle, asymptomatic alterations in cardiac function to overt, severe heart failure. This study purposed to evaluate the impact of sodium-glucose transport protein 2 inhibitors (SGLT2) inhibitors on diastolic function and endothelial health in breast cancer patients receiving chemotherapy. Materials and methods. A prospective, comparative, study was conducted at Ivano-Frankivsk Central City Clinical Hospital, Private Medical Center “Frankomed” and Lviv Private Medical Center “Rhythm” from January 2023 to May 2024. Fifty-five female patients with confirmed breast cancer and type 2 diabetes mellitus who were referred to cardiologist were enrolled and divided into three groups: group 1 (control, n = 27) received no SGLT2 inhibitors, group 2 (n = 15) received empagliflozin 10 mg daily, and group 3 (n = 13) received dapagliflozin. Echocardiographic assessments and flow-mediated dilation measurements were performed before chemotherapy initiation and after its completion. Results. The control group exhibited a significant deterioration in diastolic function, evidenced by a substantial decrease in the E/A ratio and an increase in the E/e’ ratio and isovolumetric relaxation time. In contrast, both empagliflozin and dapagliflozin groups maintained better diastolic profiles and endothelial function, as shown by less pronounced changes in echocardiographic parameters and flow-mediated dilation. Logistic regression confirmed that patients in the control group had significantly higher odds of developing abnormal follow-up indices compared with those receiving SGLT2 inhibitors. Additionally, a potential class effect was observed, with both agents offering cardioprotective benefits while exhibiting subtle differences in their impact. Conclusions. SGLT2 inhibitors appear to mitigate chemotherapy-induced cardiotoxicity by preserving diastolic function and endothelial health in patients with breast cancer concomitant with type 2 diabetes mellitus.
- 6 December 2024
- Published by ALUNA in Wiadomości Lekarskie
- Vol. 77 (10) , 1962-1968
Effectiveness of the quercetin use in patients with COVID-19 with concomitant type 2 diabetes mellitus
Aim: To conduct a comparative analysis of the effectiveness of basic therapy and basic therapy with the inclusion of quercetin in patients with COVID-19 with concomitant type 2 diabetes.Material and methods: There were examined 60 patients with COVID-19 with concomitant T2DM. Upon admission into the hospital and again after 10 days, serum levels of interleukin-6, C-reactive protein, procalcitonin, ferritin, endothelin-1 were determined, and capillaroscopy of the nail plate was performed. Patients of the group I (30) against the background of protocol therapy received 0.5 g of quercetin intravenously once a day for 10 days. Patients of the group II (30) received to basic therapy.Results: After the treatment in patients of the group I general weakness decreased, body temperature normalized, improved saturation indicators, the level of acute-phase parameters (interleukin-6, CRP and ferritin) significantly decreased, a positive effect of quercetin on the level of D-dimer in blood serum was noted, indices of pericapillary edema and hemosiderin deposition significantly decreased, indices diameter of the arterial part of the capillary and capillary network density significantly increased.Conclusions: The use of quercetin against the background of basic therapy in patients with COVID-19 and concomitant T2DM reliably reduces the level of acute-phase indices, has an important clinical significance for reducing endothelial dysfunction and for preventing thrombotic complications.
- 6 December 2024
- Published by ALUNA in Wiadomości Lekarskie
- Vol. 77 (10) , 1962-1968
Effectiveness of the quercetin use in patients with COVID-19 with concomitant type 2 diabetes mellitus
Aim: To conduct a comparative analysis of the effectiveness of basic therapy and basic therapy with the inclusion of quercetin in patients with COVID-19 with concomitant type 2 diabetes.Material and methods: There were examined 60 patients with COVID-19 with concomitant T2DM. Upon admission into the hospital and again after 10 days, serum levels of interleukin-6, C-reactive protein, procalcitonin, ferritin, endothelin-1 were determined, and capillaroscopy of the nail plate was performed. Patients of the group I (30) against the background of protocol therapy received 0.5 g of quercetin intravenously once a day for 10 days. Patients of the group II (30) received to basic therapy.Results: After the treatment in patients of the group I general weakness decreased, body temperature normalized, improved saturation indicators, the level of acute-phase parameters (interleukin-6, CRP and ferritin) significantly decreased, a positive effect of quercetin on the level of D-dimer in blood serum was noted, indices of pericapillary edema and hemosiderin deposition significantly decreased, indices diameter of the arterial part of the capillary and capillary network density significantly increased.Conclusions: The use of quercetin against the background of basic therapy in patients with COVID-19 and concomitant T2DM reliably reduces the level of acute-phase indices, has an important clinical significance for reducing endothelial dysfunction and for preventing thrombotic complications.